ABIO
ARCA biopharma, Inc.
Set alert
28.80 0.00 0.00%
2.25 Day range 28.80
52-week range unavailable
- Open
- 2.35
- Prev close
- 28.80
- Mkt cap
- 34.82M
- Vol
- 290.85K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.25
- High
- 28.80
- Forward P/E
- -3.27
- Beta
- 0.90
- Short ratio
- 62.38
- Inst. own
- 101.46%
- Dividend
- 0.00
- Ex-div date
- Aug 28, 2024
- Earnings
- Oct 16, 2024
- 50-d avg
- 39.21
- 200-d avg
- 30.93
- 1y target
- 0.00
Key statistics
- Market cap
- 34.82M
- Enterprise value
- 3.01M
- Trailing P/E
- 0.00
- Forward P/E
- -3.27
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 12.83
- EPS (TTM)
- -5.88
- Beta
- 0.90
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -4.98M
- Total cash
- 33.28M
- Total debt
- 24.00K
- Return on equity
- -20.05%
- Shares outstanding
- 1.21M
- Short % of float
- 48.08%
- 50-day average
- 39.21
- 200-day average
- 30.93
Analyst view
Consensus: none
Price target (mean) 0.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Oct 16, 2024
Expected Oct 16, 2024. Consensus EPS estimate 0.00.
Financials — quick view
ABIO Revenue — quarterly 0
ABIO Net income — quarterly -2.68M
ABIO EPS — quarterly -0.18
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 16, 2024 | Sep 1, 2024 | 0.00 | — | — | — |
| Aug 1, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| Apr 25, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Feb 1, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
| Oct 18, 2023 | Sep 1, 2023 | 0.00 | — | — | — |
| Jul 21, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 8, 2013 | Dawson James | init | — | Buy |
About ARCA biopharma, Inc.
ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- arcabio.com
News
- ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split
- ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics
- ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics
- ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics
- ARCA biopharma Announces Second Quarter 2024 Financial Results and Provides Corporate Update
- Shareholder Alert: Ademi LLP investigates Disclosure Issues involving ARCA biopharma, Inc.'s Transaction with Oruka
- Reviewing ARCA biopharma (NASDAQ:ABIO) and Cardio Diagnostics (NASDAQ:CDIO)
- 3 Short-Squeeze Stocks Ready to Soar on Roaring Kitty Rally
- ARCA BIOPHARMA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO
- ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update
Your note
Sign in to keep a note on ABIO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARRETT PETER | Beneficial Owner of more than 10% of a Class of Security | Sale | Feb 25, 2018 | 0 |
| BASKETT FOREST | Beneficial Owner of more than 10% of a Class of Security | Sale | Feb 25, 2018 | 0 |
| CABLE CAR CAPITAL LLC | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Dec 15, 2022 | 4,000,450 |
| CONWAY ROBERT E | Chairman of the Board | Purchase | May 11, 2021 | 50,000 |
| DEKKER C JEFFREY | Chief Financial Officer | Stock Award(Grant) | Dec 7, 2022 | 40,000 |
| KEUER THOMAS A | Chief Operating Officer | Stock Award(Grant) | Dec 7, 2022 | 40,730 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Bml Capital Management, Llc | 4.91% | 706,930 | 1.44M | Jun 29, 2023 |
| Western Standard, LLC | 4.37% | 630,191 | 1.28M | Jun 29, 2023 |
| Vanguard Group Inc | 3.20% | 461,613 | 937.07K | Jun 29, 2023 |
| Newtyn Management, Llc | 2.17% | 313,200 | 635.80K | Jun 29, 2023 |
| Blackrock Inc. | 1.61% | 231,959 | 470.88K | Jun 29, 2023 |
| Geode Capital Management, LLC | 1.08% | 155,635 | 315.94K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.17% | 312,166 | 633.70K | Jun 29, 2023 |
| Vanguard Extended Market Index Fund | 0.96% | 138,329 | 280.81K | Jun 29, 2023 |
| Fidelity Extended Market Index Fund | 0.39% | 55,513 | 117.13K | May 30, 2023 |
| Fidelity Total Market Index Fund | 0.37% | 52,959 | 111.74K | May 30, 2023 |
| Bridgeway Funds Inc-Ultra Small Company Fund | 0.33% | 46,948 | 95.30K | Jun 29, 2023 |
| Tekla Life Sciences Investors | 0.23% | 32,461 | 65.89K | Jun 29, 2023 |